EVALUATION OF THERAPEUTIC EFFECTS OF DEXAMETHASONE, HIGH-DOSE CYTOSINE ARABINOSIDE AND CISPLATIN REGIMEN ON PATIENTS WITH RELAPSED LYMPHOMA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

OKHOVATIAN A.; ATARIAN H.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Researcher Bulletin of Medical Sciences Year:2007 | Volume:12 | Issue:1 (55) Page(s): 23-29

Download Full-Text

Persian Verion

View:

2,896

Download:

Cites:

Information Journal Paper

Title

EVALUATION OF THERAPEUTIC EFFECTS OF DEXAMETHASONE, HIGH-DOSE CYTOSINE ARABINOSIDE AND CISPLATIN REGIMEN ON PATIENTS WITH RELAPSED LYMPHOMA

Author(s)

OKHOVATIAN A. | ATARIAN H. | Issue Writer Certificate

Keywords

RELAPSED LYMPHOMAQ3

SALVAGE REGIMENQ3

DHAP REGIMENQ3

Abstract

Background: Recurrence of hematologic malignancies is one of the main problems after early management of these diseases. Due to the poor survival, several SALVAGE REGIMENs have been suggested. To evaluate the efficacy and safety of DHAP REGIMEN in RELAPSED LYMPHOMA, we conducted this prospective trial. Materials and Methods: Sixthy patients with progressive RELAPSED LYMPHOMA were treated with a combination of Cisplatin 100 mg/m2 (continuous IV infusion over 24 hours) followed by Cytosine Arabinoside in two pulses (each at a dose of 2 g/m2 given 12 hours apart). Dexamethasone (40mg IV) was given on days 1 through 4. Vigorous hydration was reinforced by routine use of mannitol. Cycles were repeated at 3-4 weeks interval for six courses. The primary aim was to evaluate the response after six cycles. Results: Patients had a median age of 42 years old (15–70 years). They all had relapsed during or less than one year after first line chemotherapy. Out of 60 patients, 19 (32%) achieved complete remission, whereas 17 (28%) experienced partial remission. Eleven patients (18%) expired during treatment. The mean survival of patients after 2 years of follow up was 53%. Organomegaly, lymphomadenopathy, the underlying disease and serum LDH were important prognostic factors and the most frequent complication of DHAP REGIMEN was neutropenia (55%). Conclusion: Having acceptable complications, the DHAP REGIMEN was proved to be effective for patients with relapsed or refractory lymphoma. For stronger recommendation of this regimen larger scale trials are needed.

Cites

No record.

References

No record.

Cite

APA: Copy

OKHOVATIAN, A., & ATARIAN, H.. (2007). EVALUATION OF THERAPEUTIC EFFECTS OF DEXAMETHASONE, HIGH-DOSE CYTOSINE ARABINOSIDE AND CISPLATIN REGIMEN ON PATIENTS WITH RELAPSED LYMPHOMA. RESEARCHER BULLETIN OF MEDICAL SCIENCES (PEJOUHANDEH), 12(1 (55)), 23-29. SID. https://sid.ir/paper/18487/en

Vancouver: Copy

OKHOVATIAN A., ATARIAN H.. EVALUATION OF THERAPEUTIC EFFECTS OF DEXAMETHASONE, HIGH-DOSE CYTOSINE ARABINOSIDE AND CISPLATIN REGIMEN ON PATIENTS WITH RELAPSED LYMPHOMA. RESEARCHER BULLETIN OF MEDICAL SCIENCES (PEJOUHANDEH)[Internet]. 2007;12(1 (55)):23-29. Available from: https://sid.ir/paper/18487/en

IEEE: Copy

A. OKHOVATIAN, and H. ATARIAN, “EVALUATION OF THERAPEUTIC EFFECTS OF DEXAMETHASONE, HIGH-DOSE CYTOSINE ARABINOSIDE AND CISPLATIN REGIMEN ON PATIENTS WITH RELAPSED LYMPHOMA,” RESEARCHER BULLETIN OF MEDICAL SCIENCES (PEJOUHANDEH), vol. 12, no. 1 (55), pp. 23–29, 2007, [Online]. Available: https://sid.ir/paper/18487/en

Related Journal Papers